Journal article
Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 Trial
SA Rosenthal, C Hu, O Sartor, LG Gomella, MB Amin, J Purdy, JM Michalski, MG Garzotto, N Pervez, AG Balogh, GB Rodrigues, L Souhami, MN Reaume, SG Williams, R Hannan, EM Horwitz, A Raben, CA Peters, FY Feng, WU Shipley Show all
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
DOI: 10.1200/JCO.18.02158
Abstract
PURPOSE Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival (OS) and clinical outcomes among patients with high-risk prostate cancer. PATIENTS AND METHODS The multicenter randomized NRG Oncology RTOG 0521 study enrolled patients with high-risk nonmetastatic disease between 2005 and 2009. Patients were randomly assigned to receive standard long-term AS plus RT with or without adjuvant CT. RESULTS A total of 612 patients were enrolled; 563 were evaluable. Median prostate-specific antigen was 15.1 ng/mL; 53% had a Gleason s..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by Grants No. U10CA21661 (Radiation Therapy Oncology Group Operations and Statistics & Data Management Center), U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology Statistical and Data Management Center), and U24CA180803 (Imaging and Radiation Oncology Core) from the National Cancer Institute and by Sanofi.